Connect Lymphoma

About the Connect® Lymphoma Disease Registry (NCT04982471):


The Connect® Lymphoma Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, participant-level data longitudinally in participants diagnosed with various subtypes of non-Hodgkin lymphoma (NHL). The study was launched in August 2021.

This is an observational study, which means enrolled patients will receive treatment and evaluations for their disease according to the standard of care and routine clinical practice at each study site. This Disease Registry is designed to capture patient characteristics, practice patterns, and therapeutic regimens in community and academic centers when treating relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), R/R follicular lymphoma (FL), and primary mediastinal B-cell lymphoma (PMBCL). The data collected in this Registry will facilitate the evaluation of the current treatment landscape for non-Hodgkin lymphoma (NHL), including effectiveness and safety.


Patient Advocacy Groups*

*List of patient advocacy groups is non-exhaustive.